Randomized Trial of Verubecestat for Prodromal Alzheimer’s Disease

2019540 citationsJournal Articlebronze Open Access

Authors

Michael Egan

James Kost

Tiffini Voss

Yuki Mukai

Paul Aisen

Jeffrey L. Cummings · Lou Ruvo Brain Institute

Pierre N. Tariot · Alzheimer's Association

Bruno Vellas · Inserm

Christopher H. van Dyck

Merçé Boada

Abstract

Verubecestat did not improve clinical ratings of dementia among patients with prodromal Alzheimer's disease, and some measures suggested that cognition and daily function were worse among patients who received verubecestat than among those who received placebo. (Funded by Merck Sharp & Dohme; ClinicalTrials.gov number, NCT01953601.).

Topics & Keywords

Alzheimer's disease research and treatments Cholinesterase and Neurodegenerative Diseases Folate and B Vitamins Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 380, Issue 15, pp. 1408-1420

DOI: 10.1056/nejmoa1812840

Field-Weighted Citation Impact: 48.09